Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Arbormentis LLC is addressing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a streamlined administrative structure for the company's current filings. This focus within the identified art unit indicates that the company's current innovation is being evaluated against a consistent set of prior art and examination standards.
The busiest examiner for the portfolio is BENAVIDES, JENNIFER ANN, who has 1 pending office action. This examiner currently oversees all pending prosecution for the company's patent portfolio. As the only official reviewing the company's work, the examination style and preferences of BENAVIDES, JENNIFER ANN will be the primary factor in the prosecution's progress.
The presence of only a single pending office action suggests that the company's current prosecution phase is relatively quiet. While this reduces the immediate burden on the company's intellectual property budget, it also means that the company's future patent position in the biotech space is currently tied to the outcome of this specific matter. Practitioners should tailor their arguments to the specific feedback provided by this single examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559579 | POLYMER CONJUGATES OF DRUGS TARGETING 5-HT AND OTHER RECEPTORS IN THE CENTRAL NERVOUS SYSTEM (CNS) THAT ALSO TARGETS RECEPTORS OUTSIDE OF THE CNS | BENAVIDES, JENNIFER ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559579 | POLYMER CONJUGATES OF DRUGS TARGETING 5-HT AND OTHER RECEPTORS IN THE CENTRAL NERVOUS SYSTEM (CNS) THAT ALSO TARGETS RECEPTORS OUTSIDE OF THE CNS | BENAVIDES, JENNIFER ANN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18559579 | POLYMER CONJUGATES OF DRUGS TARGETING 5-HT AND OTHER RECEPTORS IN THE CENTRAL NERVOUS SYSTEM (CNS) THAT ALSO TARGETS RECEPTORS OUTSIDE OF THE CNS | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArbormentis LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer Ann Benavides has the most, with 1 of Arbormentis LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
